Publications by authors named "Mathilde Berger"

Claim this Profile
E
Exploring the Needs of People With Chronic Low Back Pain and Health Care Professionals for mHealth Devices to Support Self-Managed Physical Activity and Pain: User-Centered Design Approach.
Mathilde Berger, Anne Deblock-Bellamy, Laurence Chèze, Thomas Robert, Julie J Desrosiers

JMIR Hum Factors· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category.
Pierre-Yves Courand, Mathilde Berger, Chahinaz Moulayat, Anissa Bouali, Stéphane Dalle

JACC CardioOncol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring objective physical activity in people with chronic low back pain using accelerometers: a scoping review.
Mathilde Berger, Anne Martine Bertrand, Thomas Robert, Laurence Chèze

Front Sports Act Living· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Effects of BRAF and MEK Inhibitors: Mechanisms and Clinical Management.
Pierre-Yves Courand, Mathilde Berger, Anissa Bouali, Brahim Harbaoui, Pierre Lantelme

Curr Oncol Rep· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Samy Belkaid, Mathilde Berger, Mathilde Nouvier, Cécile Picard, Stéphane Dalle

Eur J Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: A retrospective analysis.
Mathilde Berger, Mona Amini-Adlé, Delphine Maucort-Boulch, Philip Robinson, Luc Thomas

Cancer Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
Mathilde Berger, Mona Amini-Adlé, Laura Crumbach, Etienne Paubelle, Stéphane Dalle

Eur J Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
Mathilde Berger, Mona Amini-Adlé, Laura Crumbach, Etienne Paubelle, Stéphane Dalle

Eur J Cancer· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.
Pierre Fenaux, Valeria Santini, Maria Antonietta Aloe Spiriti, Aristoteles Giagounidis, Rudolf Schlag, Mathilde Hunault Berger

Leukemia· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Mathilde Berger, Anne-Lise Legeay, Sabrine Souci, Nathalie Streichenberger, Luc Thomas

Eur J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis